Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
kamoshima, hikaru
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy	Completed	3	692	Europe, Japan, US, RoW	Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec	Eli Lilly and Company	Type 1 Diabetes, Diabetes	05/24	05/24
ACHIEVE-J, NCT06010004: A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes	Active, not recruiting	3	399	Japan	Orforglipron, LY3502970	Eli Lilly and Company	Type 2 Diabetes	06/25	06/25